Discrepancy between subjective symptoms, objective measures and disease activity indexes: the lesson of primary Sjögren's syndrome.

Mucosal dryness is a key clinical feature in primary Sjögren's syndrome (pSS) and its assessment relies on both objective measurement of residual secretion and subjective symptoms reported by patients. However, while the objective assessment and grading of glandular dysfunction can be easily performed, the spectrum of clinical symptoms encompassed by the terms 'dry eye' and 'dry mouth' is wide and heterogeneous. Therefore, patient reported outcomes (PROs) for dryness in pSS poorly correlate with the amount of glandular secretion. In addition, subjective dryness is not correlated with the severity of systemic disease and severely affects the patient quality of life even in presence of active extraglandular manifestations. The purpose of this review article is to provide an overview of glandular dysfunction in pSS as well as the impact of discrepancy between objective assessment, subjective symptom and extraglandular disease activity on disease management.

[1]  T. Lietman,et al.  Ocular Involvement in Sjögren’s Syndrome: Advances in Therapy , 2018, Current Treatment Options in Rheumatology.

[2]  R. Moots,et al.  Subjective and Objective Measures of Dryness Symptoms in Primary Sjögren's Syndrome: Capturing the Discrepancy , 2017, Arthritis care & research.

[3]  T. Teshima,et al.  Overview of Human Salivary Glands: Highlights of Morphology and Developing Processes , 2017, Anatomical record.

[4]  X. Mariette,et al.  Severe Health‐Related Quality of Life Impairment in Active Primary Sjögren's Syndrome and Patient‐Reported Outcomes: Data From a Large Therapeutic Trial , 2017, Arthritis care & research.

[5]  A. Vissink,et al.  Abatacept treatment of patients with primary Sjögren's syndrome results in a decrease of germinal centres in salivary gland tissue. , 2017, Clinical and experimental rheumatology.

[6]  Mitchell A Jackson,et al.  Dysfunctional tear syndrome: dry eye disease and associated tear film disorders – new strategies for diagnosis and treatment , 2017, Current opinion in ophthalmology.

[7]  B. Dye,et al.  Significance and Implications of Patient-reported Xerostomia in Sjögren's Syndrome: Findings From the National Institutes of Health Cohort , 2016, EBioMedicine.

[8]  D. Wong,et al.  The Proteomics of Saliva in Sjögren's Syndrome. , 2016, Rheumatic diseases clinics of North America.

[9]  M. Fernandez Castro,et al.  Oral involvement in patients with primary Sjögren's syndrome. Multidisciplinary care by dentists and rheumatologists. , 2015, Reumatologia clinica.

[10]  M. Mimura,et al.  Associations between Subjective Happiness and Dry Eye Disease: A New Perspective from the Osaka Study , 2015, PloS one.

[11]  M. Momin,et al.  A Comprehensive Review on Dry Eye Disease: Diagnosis, Medical Management, Recent Developments, and Future Challenges , 2015 .

[12]  Lyndon Jones,et al.  Infrared imaging of meibomian glands and evaluation of the lipid layer in Sjögren's syndrome patients and nondry eye controls. , 2015, Investigative ophthalmology & visual science.

[13]  G. Baron,et al.  Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI) , 2014, Annals of the rheumatic diseases.

[14]  D. Isenberg,et al.  Biologic treatment in Sjögren's syndrome. , 2014, Rheumatology.

[15]  F. Ciccia,et al.  Rituximab in primary Sjögren's syndrome: a ten-year journey , 2014, Lupus.

[16]  C. D. de Paiva,et al.  Managing Sjögren’s Syndrome and non-Sjögren Syndrome dry eye with anti-inflammatory therapy , 2014, Clinical ophthalmology.

[17]  S. Bombardieri,et al.  Concise Report , 2022 .

[18]  P. Ravaud,et al.  Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI) , 2014, Annals of the rheumatic diseases.

[19]  A. Manzo,et al.  Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study , 2013, Arthritis Research & Therapy.

[20]  P. Ravaud,et al.  European League Against Rheumatism Sjögren's Syndrome Disease Activity Index and European League Against Rheumatism Sjögren's Syndrome Patient‐Reported Index: A Complete Picture of Primary Sjögren's Syndrome Patients , 2013, Arthritis care & research.

[21]  G. Carpenter,et al.  The secretion, components, and properties of saliva. , 2013, Annual review of food science and technology.

[22]  P. Ravaud,et al.  EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjögren's syndrome , 2011, Annals of the rheumatic diseases.

[23]  De-Quan Li,et al.  IL-17 disrupts corneal barrier following desiccating stress , 2009, Mucosal Immunology.

[24]  B. Fridlund,et al.  The subjective meaning of xerostomia—an aggravating misery , 2009 .

[25]  J. Tiffany.  The normal tear film. , 2008, Developments in ophthalmology.

[26]  Christophe Baudouin,et al.  The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). , 2007, The ocular surface.

[27]  A J Bron,et al.  Functional aspects of the tear film lipid layer. , 2004, Experimental eye research.

[28]  J. Tiffany,et al.  Tears in health and disease , 2003, Eye.

[29]  S. Bowman,et al.  Validation of the Sicca Symptoms Inventory for clinical studies of Sjögren's syndrome. , 2003, The Journal of rheumatology.

[30]  S. Rogers,et al.  The development and initial validation of the Liverpool sicca index to assess symptoms and dysfunction in patients with primary Sjögren's syndrome. , 2003, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[31]  R. Morton,et al.  Quality of life and nutritional studies in Sjogren's syndrome patients with xerostomia. , 2001, The New Zealand dental journal.

[32]  R. Schiffman,et al.  Reliability and validity of the Ocular Surface Disease Index. , 2000, Archives of ophthalmology.

[33]  Sheila M. Williams,et al.  The Xerostomia Inventory: a multi-item approach to measuring dry mouth. , 1999, Community dental health.

[34]  K. Tsubota,et al.  Meibomian gland dysfunction in patients with Sjögren syndrome. , 1998, Ophthalmology.

[35]  C. Baldini,et al.  One year in review 2017: systemic vasculitis. , 2017, Clinical and experimental rheumatology.